FDA warns against the Muscle Drugs, SARMs
The US Food and Drug Administration (FDA) has issued a warning on the muscle drug, SARMs, stating that products containing selective androgen receptor modulators(SARMs) may result in serious or life-threatening events, including testicular atrophy, heart attack, hallucinations, and liver damage.
The warning, released on April 26, was prompted by social media influencers' marketing of SARMs as a dietary supplement, promising easy muscle gain and improved athletic performance. Despite their potential for treating health conditions such as osteoporosis, Alzheimer's disease, and multiple sclerosis, SARMs have not been approved by the FDA, and several companies have been warned about distributing SARMs-containing products.
Studies and reports submitted to the FDA have revealed a range of adverse health events associated with SARMs, including sleep disturbances, testicular shrinkage, psychosis or hallucinations, sexual dysfunction, liver injury and acute liver failure, infertility, miscarriage, and an increased risk of heart attack or stroke.
The FDA advises against using SARMs, and individuals experiencing side effects should seek medical advice. Furthermore, the agency recommends consulting healthcare providers before using any performance-enhancing products to ensure they do not contain harmful substances.
IJCP Editorial Team
Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.
More FAQs by IJCP Editorial Team
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please login to comment on this article